Lymphatic dysregulation in intestinal inflammation: New insights into inflammatory bowel disease pathomechanisms

Lymphology

Volumn 47, Issue 1, 2014, Pages 3-27

  Becker, F ^a,c   Yi, P ^a   Al Kofahi, M ^a   Ganta, V C ^a   Morris, J ^b   Alexander, J Steven ^a  

^a LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b Louisiana State University Health Sciences Center at Shreveport   (United States)

^c UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

Endothelin; Histamine; Inflammatory bowel disease; Intestinal lymphangiogenesis; Lymphatic pumping; Lymphatic remodeling; NF B; TLR; VEGFR 3; VIP

Indexed keywords

ADENOSINE TRIPHOSPHATE SENSITIVE POTASSIUM CHANNEL; ALCOHOL; BETA CHEMOKINE; CHEMOKINE SCAVENGING RECEPTOR D6; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ENDOTHELIN; GAMMA INTERFERON; HISTAMINE H1 RECEPTOR; HISTAMINE H2 RECEPTOR; HISTAMINE H3 RECEPTOR; HISTAMINE H4 RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1BETA; INTERLEUKIN 6; NITRIC OXIDE; PROSTANOID; TIGHT JUNCTION PROTEIN; TOLL LIKE RECEPTOR 1; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 5; TOLL LIKE RECEPTOR 6; TOLL LIKE RECEPTOR 7; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN RECEPTOR 3; VASOACTIVE INTESTINAL POLYPEPTIDE;

ABDOMINAL FAT; ADAPTIVE IMMUNITY; ALCOHOL CONSUMPTION; B LYMPHOCYTE; CROHN DISEASE; CYTOKINE RELEASE; DENDRITIC CELL; ENDOTHELIUM CELL; GENE OVEREXPRESSION; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; INFLAMMATORY BOWEL DISEASE; INNATE IMMUNITY; INTERSTITIAL FLUID; INTESTINAL LIPID CLEARANCE; LEYDIG CELL; LIPID STORAGE; LYMPH FLOW; LYMPH VESSEL; LYMPH VESSEL ENDOTHELIUM; LYMPHANGIOGENESIS; LYMPHANGITIS; LYMPHATIC SYSTEM; LYMPHATIC SYSTEM DISEASE; MACROPHAGE; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; SMOOTH MUSCLE CONTRACTILITY; SMOOTH MUSCLE FIBER; T LYMPHOCYTE; ULCERATIVE COLITIS; VASCULAR SMOOTH MUSCLE;

ANIMALS; ANTI-INFLAMMATORY AGENTS; GASTROINTESTINAL AGENTS; HUMANS; INFLAMMATION MEDIATORS; INFLAMMATORY BOWEL DISEASES; INTESTINES; LYMPHANGIOGENESIS; LYMPHATIC VESSELS; SIGNAL TRANSDUCTION;

EID: 84903132454     PISSN: 00247766     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (190)

1. Molodecky, NA, IS Soon, DM Rabi, et al: Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology. 142 (2012), 46-54.e42; quiz e30.
2. Xavier, RJ, DK Podolsky: Unravelling the pathogenesis of inflammatory bowel disease. Nature 448 (2007), 427-434. (Pubitemid 47123518)
3. Baumgart, DC, WJ Sandborn: Crohn's disease. Lancet 380 (2012),1590-1605.
4. Scharl, M, G Rogler: Inflammatory bowel disease pathogenesis: What is new? Curr. Opin. Gastroenterol. 28 (2012), 301-309.
5. Ordás, I, L Eckmann, M Talamini, et al: Ulcerative colitis. Lancet 380 (2012), 1606-1619.
6. Baumgart, DC, SR Carding: Inflammatory bowel disease: Cause and immunobiology. Lancet 369 (2007),1627-1640. (Pubitemid 46722636)
7. Pastorelli L, C De Salvo, JR Mercado, et al: Central role of the gut epithelial barrier in the pathogenesis of chronic intestinal inflammation: Lessons learned from animal models and human genetics. Front. Immunol. 4 (2013), 280.
8. Danese, S: Role of the vascular and lymphatic endothelium in the pathogenesis of inflammatory bowel disease: "Brothers in arms." Gut 60 (2011), 998-1008.
9. Chidlow, JH, Jr, D Shukla, MB Grisham, et al: Pathogenic angiogenesis in IBD and experimental colitis: New ideas and therapeutic avenues. Am. J. Physiol. Gastrointest. Liver Physiol. 293 (2007), G5-G18. (Pubitemid 47105158)
10. Langston, W, JR Chidlow Jr, BA Booth, et al: Regulation of endothelial glutathione by ICAM-1 governs VEGF-A-mediated eNOS activity and angiogenesis. Free Radic. Biol. Med. 42 (2007),720-729. (Pubitemid 46205151)
11. Alexander, JS, GV Chaitanya, MB Grisham, et al: Emerging roles of lymphatics in inflammatory bowel disease. Ann. NY Acad. Sci 1207 (Suppl 1) (2010), E75-85.
12. Crohn, BB, L Ginzburg, GD Oppenheimer: Regional ileitis: A pathologic and clinical entity. J Am Med Assoc 99 (1932), 1323-1329.
13. Van Kruiningen, HJ, J-F Colombel: The forgotten role of lymphangitis in Crohn's disease. Gut 57 (2008),1-4.
14. Kaiserling, E, S Kröber, S Geleff: Lymphatic vessels in the colonic mucosa in ulcerative colitis. Lymphology 36 (2003), 52-61. (Pubitemid 36900181)
15. Rahier, J-F, S De Beauce, L Dubuquoy, et al: Increased lymphatic vessel density and lymphangiogenesis in inflammatory bowel disease. Aliment Pharmacol. Ther. 34 (2011), 533-543.
16. Von Der Weid, P-Y, S Rehal: Lymphatic pump function in the inflamed gut. Ann. NY Acad. Sci. 1207 (Suppl 1) (2010), E69-74.
17. Linares, PM, JP Gisbert: Role of growth factors in the development of lymphangiogenesis driven by inflammatory bowel disease: A review. Inflamm. Bowel Dis. 17 (2011), 1814-1821.
18. Nesis, L, EE Sterns: Lymph flow from the colon under varying conditions. Ann. Surg. 177 (1973), 422-427.
19. Sheppard, MS, EE Sterns: The role of vascular and lymph capillaries in the clearance of interstitially injected albumin in acute and chronic inflammation of the colon. Surg. Gynecol. Obstet. 139 (1974), 707-711.
20. Colombel, J-F, BG Feagan, WJ Sandborn, et al: Therapeutic drug monitoring of biologics for inflammatory bowel disease. Inflamm. Bowel Dis. 18 (2012), 349-358.
21. Kalima, TV: Experimental lymphatic obstruction in the ileum. Ann. Chir. Gynaecol. Fenn. 59 (1970), 187-201.
22. Zampell, JC, S Aschen, ES Weitman, et al: Regulation of adipogenesis by lymphatic fluid stasis: Part I. Adipogenesis, fibrosis, and inflammation. Plast Reconstr. Surg. 129 (2012), 825-834.
23. Von der Weid, P-Y, M Muthuchamy: Regulatory mechanisms in lymphatic vessel contraction under normal and inflammatory conditions. Pathophysiol. 17 (2010), 263-276.
24. Von der Weid, P-Y, S Rehal, JG Ferraz: Role of the lymphatic system in the pathogenesis of Crohn's disease. Curr. Opin. Gastroenterol. 27 (2011), 335-341.
25. Choi, I, S Lee, H Kyoung Chung, et al: 9-cis retinoic acid promotes lymphangiogenesis and enhances lymphatic vessel regeneration: Therapeutic implications of 9-cis retinoic acid for secondary lymphedema. Circulation 125 (2012), 872-882.
26. Hodge, LM, HF Downey: Lymphatic pump treatment enhances the lymphatic and immune systems. Exp. Biol. Med. 236 (2011), 1109-1115.
27. Margaris, KN, RA Black: Modelling the lymphatic system: Challenges and opportunities. J. Roy. Soc. 9 (2012), 601-612.
28. Schander, A, HF Downey, LM Hodge: Lymphatic pump manipulation mobilizes inflammatory mediators into lymphatic circulation. Exp. Biol. Med. 237 (2012), 58-63.
29. Baluk, P, J Fuxe, H Hashizume, et al: Functionally specialized junctions between endothelial cells of lymphatic vessels. J. Exp. Med. 204 (2007), 2349-2362. (Pubitemid 47529321)
30. Negrini, D, A Moriondo: Lymphatic anatomy and biomechanics. J. Physiol. 589 (2011), 2927-2934.
31. Zawieja, DC: Contractile physiology of lymphatics. Lymphat. Res. Biol. 7 (2009), 87-96.
32. Ricciotti, E, GA FitzGerald: Prostaglandins and inflammation. Arterioscler. Thromb. Vasc. Biol. 31 (2011), 986-1000.
33. Smyth EM, T Grosser, M Wang, et al: Prostanoids in health and disease. J. Lipid Res. 50 (2009), Suppl:S423-428.
34. Harris, DW, CH Swan: Increased synthesis of prostaglandins in ulcerative colitis. Lancet 2 (1977), 196.
35. Zifroni, A, AJ Treves, DB Sachar, et al: Prostanoid synthesis by cultured intestinal epithelial and mononuclear cells in inflammatory bowel disease. Gut 24 (1983), 659-664. (Pubitemid 13066631)
36. Chan, AK, N Vergnolle, MD Hollenberg, et al: Proteinase-activated receptor 2 activation modulates guinea-pig mesenteric lymphatic vessel pacemaker potential and contractile activity. J. Physiol. 560 (2004), 563-576. (Pubitemid 39440114)
37. Johnston, MG, C Feuer: Suppression of lymphatic vessel contractility with inhibitors of arachidonic acid metabolism. J. Pharmacol. Exp. Ther. 226 (1983), 603-607. (Pubitemid 13041543)
38. Johnston, MG, JL Gordon: Regulation of lymphatic contractility by arachidonate metabolites. Nature 293 (1981), 294-297. (Pubitemid 11016259)
39. Mizuno, R, A Koller, G Kaley: Regulation of the vasomotor activity of lymph microvessels by nitric oxide and prostaglandins. Am. J. Physiol. 274 (1998), R790-796.
40. Von der Weid, PY: Review article: Lymphatic vessel pumping and inflammation - the role of spontaneous constrictions and underlying electrical pacemaker potentials. Aliment Pharmacol. Ther. 15 (2001), 1115-1129.
41. Rehal, S, P Blanckaert, S Roizes, et al: Characterization of biosynthesis and modes of action of prostaglandin E2 and prostacyclin in guinea pig mesenteric lymphatic vessels. Br. J. Pharmacol. 158 (2009), 1961-1970.
42. Wu, TF, CJ Carati, WK Macnaughton, et al: Contractile activity of lymphatic vessels is altered in the TNBS model of guinea pig ileitis. Am. J. Physiol. Gastrointest. Liver Physiol. 291 (2006), G566-574. (Pubitemid 44511674)
43. Bjarnason, I, A So, AJ Levi, et al: Intestinal permeability and inflammation in rheumatoid arthritis: Effects of non-steroidal anti-inflammatory drugs. Lancet 324 (1984), 1171-1174.
44. Bjarnason, I, J Hayllar, AJ MacPherson, et al: Side effects of nonsteroidal antiinflammatory drugs on the small and large intestine in humans. Gastroenterology 104 (1993), 1832-1847. (Pubitemid 23235480)
45. Davies, NM: Review article: Non-steroidal anti-inflammatory drug-induced gastrointestinal permeability. Aliment Pharmacol. Ther. 12 (1998), 303-320.
46. Halter, F, AS Tarnawski, A Schmassmann, et al: Cyclooxygenase 2-implications on maintenance of gastric mucosal integrity and ulcer healing: controversial issues and perspectives. Gut 49 (2001), 443-453. (Pubitemid 32802583)
47. Jackson, LM, KC Wu, YR Mahida, et al: Cyclooxygenase (COX) 1 and 2 in normal, inflamed, and ulcerated human gastric mucosa. Gut 47 (2000), 762-770.
48. Takezono, Y, T Joh, T Oshima, et al: Role of prostaglandins in maintaining gastric mucus-cell permeability against acid exposure. J. Lab. Clin. Med. 143 (2004), 52-58. (Pubitemid 38156416)
49. Nathan, C, QW Xie: Nitric oxide synthases: Roles, tolls, and controls. Cell 78 (1994), 915-918. (Pubitemid 24292319)
50. Kubes, P, DM McCafferty: Nitric oxide and intestinal inflammation. Am. J. Med. 109 (2000), 150-158.
51. Singer, II, DW Kawka, S Scott, et al: Expression of inducible nitric oxide synthase and nitrotyrosine in colonic epithelium in inflammatory bowel disease. Gastroenterology 111 (1996), 871-885. (Pubitemid 26327590)
52. Binion, DG, S Fu, KS Ramanujam, et al: iNOS expression in human intestinal microvascular endothelial cells inhibits leukocyte adhesion. Am. J. Physiol. 275 (1998), G592-603.
53. Binion, DG, P Rafiee, KS Ramanujam, et al: Deficient iNOS in inflammatory bowel disease intestinal microvascular endothelial cells results in increased leukocyte adhesion. Free Radic. Biol. Med. 29 (2000), 881-888.
54. Ohhashi, T, S Yokoyama: Nitric oxide and the lymphatic system. Jpn. J. Physiol. 44 (1994), 327-342.
55. Scallan, JP, MJ Davis: Genetic removal of basal nitric oxide enhances contractile activity in isolated murine collecting lymphatic vessels. J. Physiol. 591 (2013), 2139-2156.
56. Mathias, R, P-Y von der Weid: Involvement of the NO-cGMP-K(ATP) channel pathway in the mesenteric lymphatic pump dysfunction observed in the guinea pig model of TNBS-induced ileitis. Am. J. Physiol. Gastrointest. Liver Physiol. 304 (2013), G623-634.
57. Von der Weid, P-Y, DC Zawieja: Lymphatic smooth muscle: The motor unit of lymph drainage. Int. J. Biochem. Cell Biol. 36 (2004), 1147-1153.
58. Parsons, ME, CR Ganellin: Histamine and its receptors. Br. J. Pharmacol. 147 (2006), Suppl 1:S127-135.
59. Zhang, M, RL Thurmond, PJ Dunford: The histamine H(4) receptor: A novel modulator of inflammatory and immune disorders. Pharmacol. Ther. 113 (2007), 594-606. (Pubitemid 46371410)
60. Dale, HH, PP Laidlaw: The physiological action of β- iminazolylethylamine. J. Physiol. 41 (1910), 318-344.
61. Lloyd, G, FH Green, H Fox, et al: Mast cells and immunoglobulin E in inflammatory bowel disease. Gut 16 (1975), 861-865.
62. De Winter, BY, RM van den Wijngaard, WJ de Jonge: Intestinal mast cells in gut inflammation and motility disturbances. Biochim. Biophys. Acta 1822 (2012), 66-73.
63. Knutson, L, O Ahrenstedt, B Odlind, et al: The jejunal secretion of histamine is increased in active Crohn's disease. Gastroenterology 98 (1990), 849-854. (Pubitemid 20095834)
64. Raithel, M, M Matek, HW Baenkler, et al: Mucosal histamine content and histamine secretion in Crohn's disease, ulcerative colitis and allergic enteropathy. Int. Arch. Allergy Immunol. 108 (1995), 127-133.
65. Swanson, GR, S Sedghi, A Farhadi, et al: Pattern of alcohol consumption and its effect on gastrointestinal symptoms in inflammatory bowel disease. Alcohol 44 (2010), 223-228.
66. Fox, JLR, P-Y von der Weid: Effects of histamine on the contractile and electrical activity in isolated lymphatic vessels of the guinea-pig mesentery. Br. J. Pharmacol. 136 (2002), 1210-1218. (Pubitemid 34970074)
67. Pan'kova, MN, GI Lobov, VN Chikhman, et al: [Effects of histamine on contractile activity of lymphatic node capsules. The NO role]. Ross Fiziol Zhurnal Im IM Sechenova Ross Akad Nauk 97 (2011), 633-640.
68. Delgado, M, D Pozo, D Ganea: The significance of vasoactive intestinal peptide in immunomodulation. Pharmacol. Rev. 56 (2004), 249-290. (Pubitemid 38720831)
69. Gonzalez-Rey, E, P Anderson, M Delgado: Emerging roles of vasoactive intestinal peptide: a new approach for autoimmune therapy. Ann. Rheum. Dis. 66 (Suppl 3) (2007), iii 70-76.
70. Gutiérrez-Cañas, I, Y Juarranz, B Santiago, et al: Immunoregulatory properties of vasoactive intestinal peptide in human T cell subsets: Implications for rheumatoid arthritis. Brain Behav. Immun. 22 (2008), 312-317. (Pubitemid 351172708)
71. Maggi, CA, A Giachetti, RD Dey, et al: Neuropeptides as regulators of airway function: Vasoactive intestinal peptide and the tachykinins. Physiol. Rev. 75 (1995), 277-322.
72. Smalley, SGR, PA Barrow, N Foster: Immunomodulation of innate immune responses by vasoactive intestinal peptide (VIP): Its therapeutic potential in inflammatory disease. Clin. Exp. Immunol. 157 (2009), 225-234.
73. Martínez, C, M Delgado, D Pozo, et al: Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide modulate endotoxin-induced IL-6 production by murine peritoneal macrophages. J. Leuk. Biol. 63 (1998), 591-601. (Pubitemid 28193772)
74. Ganea, D: Regulatory effects of vasoactive intestinal peptide on cytokine production in central and peripheral lymphoid organs. Adv. Neuroimmunol. 6 (1996), 61-74.
75. Leister, I, J Sydow, T Stojanovic, et al: Impact of vasoactive intestinal polypeptide and gastrin-releasing peptide on small bowel microcirculation and mucosal injury after hepatic ischemia/reperfusion in rats. Int. J. Colorectal Dis. 20 (2005), 42-48. (Pubitemid 40057876)
76. Yang, H, Y Jin, CH Wang, et al: Effects of exogenous vasoactive intestinal peptide on mesenteric lymph pathway during early intestinal ischemia-reperfusion injury in rats. Regul. Pept. 186 (2013), 36-42.
77. Von der Weid, P-Y, S Rehal, P Dyrda, et al: Mechanisms of VIP-induced inhibition of the lymphatic vessel pump. J. Physiol. 590 (2012), 2677-2691.
78. Mignini, F, M Sabbatini, L Coppola, et al: Analysis of nerve supply pattern in human lymphatic vessels of young and old men. Lymphat. Res. Biol. 10 (2012), 189-197.
79. Kubota, Y, RE Petras, CA Ottaway, et al: Colonic vasoactive intestinal peptide nerves in inflammatory bowel disease. Gastroenterology 102 (1992), 1242-1251.
80. Abad, C, C Martinez, MG Juarranz, et al: Therapeutic effects of vasoactive intestinal peptide in the trinitrobenzene sulfonic acid mice model of Crohn's disease. Gastroenterology 124 (2003), 961-971. (Pubitemid 36389799)
81. Arranz, A, C Abad, Y Juarranz, et al: Vasoactive intestinal peptide as a healing mediator in Crohn's disease. Neuroimmunomodulation 15 (2008), 46-53.
82. Gomariz, RP, A Arranz, C Abad, et al: Time-course expression of Toll-like receptors 2 and 4 in inflammatory bowel disease and homeostatic effect of VIP. J. Leukoc. Biol. 78 (2005), 491-502. (Pubitemid 41061321)
83. Newman, R, N Cuan, T Hampartzoumian, et al: Vasoactive intestinal peptide impairs leucocyte migration but fails to modify experimental murine colitis. Clin. Exp. Immunol. 139 (2005), 411-420. (Pubitemid 40333252)
84. Prasse, A, G Zissel, N Lützen, et al: Inhaled vasoactive intestinal peptide exerts immunoregulatory effects in sarcoidosis. Am. J. Respir. Crit. Care Med. 182 (2010), 540-548.
85. Burisch, J, N Pedersen, S Cukovic-Cavka, et al: Environmental factors in a population-based inception cohort of inflammatory bowel disease patients in Europe - An ECCO-EpiCom study. J. Crohns Colitis (2013) [Epub ahead of print]
86. Yi, P, J Pang, JS Alexander, et al: The endotoxin/toll-like receptor-4 axis mediates gut microvascular dysfunction associated with post-prandial lipidemia. BMC Physiol. 13 (2013), 12.
87. Lakatos, PL, T Szamosi, L Lakatos: Smoking in inflammatory bowel diseases: Good, bad or ugly? World J. Gastroenterol. 13 (2007), 6134-6139.
88. Cohen, AB, D Lee, MD Long, et al: Dietary patterns and self-reported associations of diet with symptoms of inflammatory bowel disease. Dig. Dis. Sci. 58 (2013), 1322-1328.
89. Keshavarzian, A, JZ Fields, J Vaeth, et al: The differing effects of acute and chronic alcohol on gastric and intestinal permeability. Am. J. Gastroenterol. 89 (1994), 2205-2211. (Pubitemid 24363671)
90. Bartos, V, V Brzek: Effect of acute ethanol administration on the thoracic duct lymph flow in man. Lymphology 11 (1978), 54-56. (Pubitemid 8359807)
91. Hayashi, H, K Nakata, Y Mótohashi, et al: Acute inhibition of lipid transport in rat intestinal lymph by ethanol administration. Alcohol 27 (1992), 627-632. (Pubitemid 23077382)
92. Souza-Smith, FM, KM Kurtz, PE Molina, et al: Adaptation of mesenteric collecting lymphatic pump function following acute alcohol intoxication. Microcirc. 17 (2010), 514-524.
93. Hou, JK, D Lee, J Lewis: Diet and inflammatory bowel disease: Review of patient-targeted recommendations. Clin. Gastroenterol. Hepatol. (2013) [Epub ahead of print]
94. Tonelli, P, J Martellucci, M Lucchese, et al: Preliminary Results of the influence of the in vivo use of a lymphatic dye (Patent Blue V) in the surgical treatment of Crohn's disease. Surg. Innov. (2013), E-pub ahead of print, Nov 19.
95. Tonelli, F, F Giudici, G Liscia: Is lymphatic status related to regression of inflammation in Crohn's disease? World J. Gastrointest. Surg. 4 (2012), 228-233.
96. Batra, A, T Stroh, B Siegmund: Extraluminal factors contributing to inflammatory bowel disease. World J. Gastroenterol. 17 (2011), 572-577.
97. Peyrin-Biroulet, L, M Chamaillard, F Gonzalez, et al: Mesenteric fat in Crohn's disease: A pathogenetic hallmark or an innocent bystander? Gut 56 (2007), 577-583. (Pubitemid 46580516)
98. Desreumaux, P, O Ernst, K Geboes, et al: Inflammatory alterations in mesenteric adipose tissue in Crohn's disease. Gastroenterology 117 (1999), 73-81. (Pubitemid 29297622)
99. Sheehan, AL, BF Warren, MW Gear, et al: Fat-wrapping in Crohn's disease: pathological basis and relevance to surgical practice. Br. J. Surg. 79 (1992), 955-958.
100. Colombel, JF, CA Solem, WJ Sandborn, et al: Quantitative measurement and visual assessment of ileal Crohn's disease activity by computed tomography enterography: Correlation with endoscopic severity and C reactive protein. Gut 55 (2006), 1561-1567. (Pubitemid 44629202)
101. Paul, G, A Schäffler, M Neumeier, et al: Profiling adipocytokine secretion from creeping fat in Crohn's disease. Inflamm. Bowel Dis. 12 (2006), 471-477.
102. Harvey, NL, RS Srinivasan, ME Dillard, et al: Lymphatic vascular defects promoted by Prox1 haploinsufficiency cause adult-onset obesity. Nat. Genet. 37 (2005), 1072-1081. (Pubitemid 41486659)
103. Lund, PK, RJ Rigby: What are the mechanisms of fibrosis in IBD? Inflamm. Bowel Dis. 14 (2008), Suppl 2:S127-128.
104. Zhao, L, M-J Kwon, S Huang, et al: Differential modulation of Nods signaling pathways by fatty acids in human colonic epithelial HCT116 cells. J. Biol. Chem. 282 (2007), 11618-11628. (Pubitemid 47100703)
105. Chen, J, JS Alexander, AW Orr: Integrins and their extracellular matrix ligands in lymphangiogenesis and lymph node metastasis. Int. J. Cell. Biol. 2012 (2012), 853703.
106. Lim, HY, JM Rutkowski, J Helft, et al: Hypercholesterolemic mice exhibit lymphatic vessel dysfunction and degeneration. Am. J. Pathol. 175 (2009), 1328-1337.
107. Lim, HY, CH Thiam, KP Yeo, et al: Lymphatic vessels are essential for the removal of cholesterol from peripheral tissues by SR-BI-mediated transport of HDL. Cell. Metab. 17 (2013), 671-684.
108. Sasaki, M, S Bharwani, P Jordan, et al: The 3-hydroxy-3-methylglutaryl- CoA reductase inhibitor pravastatin reduces disease activity and inflammation in dextran-sulfate induced colitis. J. Pharmacol. Exp. Ther. 305 (2003), 78-85. (Pubitemid 36373837)
109. Backhed, F, PA Crawford, D O'Donnell, et al: Postnatal lymphatic partitioning from the blood vasculature in the small intestine requires fasting-induced adipose factor. Proc. Natl. Acad. Sci. USA 104 (2007), 606-611. (Pubitemid 46123072)
110. Mandard, S, F Zandbergen, E van Straten, et al: The fasting-induced adipose factor/angiopoietin-like protein 4 is physically associated with lipoproteins and governs plasma lipid levels and adiposity. J. Biol. Chem. 281 (2006), 934-944.
111. Geleff, S, SF Schoppmann, G Oberhuber: Increase in podoplanin-expressing intestinal lymphatic vessels in inflammatory bowel disease. Virchows Arch. Int. J. Pathol. 442 (2003), 231-237. (Pubitemid 36399216)
112. Fogt, F, TL Pascha, PJ Zhang, et al: Proliferation of D2-40-expressing intestinal lymphatic vessels in the lamina propria in inflammatory bowel disease. Int. J. Mol. Med. 13 (2004), 211-214.
113. Pedica, F, C Ligorio, P Tonelli, et al: Lymphangiogenesis in Crohn's disease: An immunohistochemical study using monoclonal antibody D2-40. Virchows Arch. Int. J. Pathol. 452 (2008), 57-63.
114. Ganta, VC, W Cromer, GL Mills, et al: Angiopoietin-2 in experimental colitis. Inflamm. Bowel Dis. 16 (2010), 1029-1039.
115. Cromer, W, MH Jennings, Y Odaka, et al: Murine rVEGF164b, an inhibitory VEGF reduces VEGF-A-dependent endothelial proliferation and barrier dysfunction. Microcirc. 17 (2010), 536-547.
116. Jeon, B-H, C Jang, J Han, et al: Profound but dysfunctional lymphangiogenesis via vascular endothelial growth factor ligands from CD11b+ macrophages in advanced ovarian cancer. Cancer Res. 68 (2008), 1100-1109. (Pubitemid 351272228)
117. Veikkola, T, L Jussila, T Makinen, et al: Signalling via vascular endothelial growth factor receptor-3 is sufficient for lymphangiogenesis in transgenic mice. EMBO J. 20 (2001), 1223-1231. (Pubitemid 32233963)
118. Alitalo, K, T Tammela, TV Petrova: Lymphangiogenesis in development and human disease. Nature 438 (2005), 946-953. (Pubitemid 43093960)
119. Mäkinen, T, L Jussila, T Veikkola, et al: Inhibition of lymphangiogenesis with resulting lymphedema in transgenic mice expressing soluble VEGF receptor-3. Nat. Med. 7 (2001), 199-205. (Pubitemid 32148487)
120. Baluk, P, T Tammela, E Ator, et al: Pathogenesis of persistent lymphatic vessel hyperplasia in chronic airway inflammation. J. Clin. Invest. 115 (2005), 247-257. (Pubitemid 40385467)
121. Roberts, N, B Kloos, M Cassella, et al: Inhibition of VEGFR-3 activation with the antagonistic antibody more potently suppresses lymph node and distant metastases than inactivation of VEGFR-2. Cancer Res. 66 (2006), 2650-2657.
122. Luo, Y, L Liu, D Rogers, et al: Rapamycin inhibits lymphatic endothelial cell tube formation by downregulating vascular endothelial growth factor receptor 3 protein expression. Neoplasia 14 (2012), 228-237.
123. Massey, DCO, F Bredin, M Parkes: Use of sirolimus (rapamycin) to treat refractory Crohn's disease. Gut 57 (2008), 1294-1296.
124. Albuquerque, RJC, T Hayashi, WG Cho, et al: Alternatively spliced vascular endothelial growth factor receptor-2 is an essential endogenous inhibitor of lymphatic vessel growth. Nat. Med. 15 (2009), 1023-1030.
125. Luo, Y, W Chen, H Zhou, et al: Cryptotanshinone inhibits lymphatic endothelial cell tube formation by suppressing VEGFR-3/ERK and small GTPase pathways. Cancer Prev. Res. 4 (2011), 2083-2091.
126. Luo, Y, H Zhou, L Liu, et al: The fungicide ciclopirox inhibits lymphatic endothelial cell tube formation by suppressing VEGFR-3-mediated ERK signaling pathway. Oncogene 30 (2011), 2098-2107.
127. Beddy, D, RWG Watson, JM Fitzpatrick, et al: Increased vascular endothelial growth factor production in fibroblasts isolated from strictures in patients with Crohn's disease. Br. J. Surg. 91 (2004), 72-77. (Pubitemid 38122053)
128. Breslin, JW, N Gaudreault, KD Watson, et al: Vascular endothelial growth factor-C stimulates the lymphatic pump by a VEGF receptor-3-dependent mechanism. Am. J. Physiol. - Heart Circ. Physiol. 293 (2007), H709-H718. (Pubitemid 47105133)
129. Breslin, JW, KM Kurtz: Lymphatic endothelial cells adapt their barrier function in response to changes in shear stress. Lymphat. Res. Biol. 7 (2009), 229-237.
130. Bonizzi, G, M Karin: The two NF-kappaB activation pathways and their role in innate and adaptive immunity. Trends Immunol. 25 (2004), 280-288. (Pubitemid 38610351)
131. DiDonato, JA, F Mercurio, M Karin: NF-B and the link between inflammation and cancer. Immunol. Rev. 246 (2012), 379-400.
132. Vallabhapurapu, S, M Karin: Regulation and function of NF-kappaB transcription factors in the immune system. Annu. Rev. Immunol. 27 (2009), 693-733.
133. Rothwarf, DM, M Karin: The NF-kappa B activation pathway: A paradigm in information transfer from membrane to nucleus. Sci. Signal Transduct. Knowl. Environ. 1999 (1999), RE1.
134. Atreya, I, R Atreya, MF Neurath: NF-kappaB in inflammatory bowel disease. J. Intern. Med. 263 (2008), 591-596.
135. Flister, MJ, LD Volk, S Ran: Characterization of Prox1 and VEGFR-3 expression and lymphatic phenotype in normal organs of mice lacking p50 subunit of NF-κB. Microcirc. 18 (2011), 85-101.
136. Saban, MR, S Mémet, DG Jackson, et al: Visualization of lymphatic vessels through NF-kappaB activity. Blood 104 (2004), 3228-3230. (Pubitemid 39507139)
137. Flister, MJ, A Wilber, KL Hall, et al: Inflammation induces lymphangiogenesis through up-regulation of VEGFR-3 mediated by NF-kappaB and Prox1. Blood 115 (2010), 418-429.
138. Schmidt-Ullrich, R, S Mémet, A Lilienbaum, et al: NF-kappaB activity in transgenic mice: developmental regulation and tissue specificity. Dev. 122 (1996), 2117-2128. (Pubitemid 26235812)
139. Ran, S, L Volk, K Hall, et al: Lymphangiogenesis and lymphatic metastasis in breast cancer. Pathophysiol. 17 (2010), 229-251.
140. Aurora, AB, AB Aurora, D Biyashev, et al: NF-kappaB balances vascular regression and angiogenesis via chromatin remodeling and NFAT displacement. Blood 116 (2010), 475-484.
141. Tabruyn, SP, AW Griffioen: NF-kappa B: A new player in angiostatic therapy. Angiogenesis 11 (2008), 101-106.
142. Tabruyn, SP, S Mémet, P Avé, et al: NF-kappaB activation in endothelial cells is critical for the activity of angiostatic agents. Mol. Cancer Ther. 8 (2009), 2645-2654.
143. Friedrichs, F, L Henckaerts, S Vermeire, et al: The Crohn's disease susceptibility gene DLG5 as a member of the CARD interaction network. J. Mol. Med. 86 (2008), 423-432.
144. Auphan, N, JA DiDonato, C Rosette C, et al: Immunosuppression by glucocorticoids: Inhibition of NF-kappa B activity through induction of I kappa B synthesis. Science 270 (1995), 286-290.
145. Weber, CK, S Liptay, T Wirth, et al: Suppression of NF-kappaB activity by sulfasalazine is mediated by direct inhibition of IkappaB kinases alpha and beta. Gastroenterology 119 (2000), 1209-1218.
146. Avraham, T, JC Zampell, A Yan, et al: Th2 differentiation is necessary for soft tissue fibrosis and lymphatic dysfunction resulting from lymphedema. FASEB J. 27 (2013), 1114-1126.
147. Brideau, G, MJ Makinen, H Elamaa, et al: Endostatin overexpression inhibits lymphangiogenesis and lymph node metastasis in mice. Cancer Res 67 (2007), 11528-11535.
148. Kataru, RP, H Kim, C Jang, et al: T lymphocytes negatively regulate lymph node lymphatic vessel formation. Immunity 34 (2011), 96-107.
149. Babyatsky, MW, G Rossiter, DK Podolsky: Expression of transforming growth factors alpha and beta in colonic mucosa in inflammatory bowel disease. Gastroenterology 110 (1996), 975-984. (Pubitemid 26113734)
150. Monteleone, I, M Sarra, F Pallone, et al: Th17-related cytokines in inflammatory bowel diseases: Friends or foes? Curr. Mol. Med. 12 (2012), 592-597.
151. Zampell, JC, A Yan, T Avraham, et al: Temporal and spatial patterns of endogenous danger signal expression after wound healing and in response to lymphedema. Am. J. Physiol. Cell. Physiol. 300 (2011), C1107-1121.
152. Heldin, CH, K Miyazono, P ten Dijke: TGF-beta signalling from cell membrane to nucleus through SMAD proteins. Nature 390 (1997), 465-471. (Pubitemid 28013118)
153. Massagué, J, D Wotton: Transcriptional control by the TGF-beta/Smad signaling system. EMBO J. 19 (2000), 1745-1754. (Pubitemid 30204386)
154. Wynn, TA: Cellular and molecular mechanisms of fibrosis. J. Pathol. 214 (2008), 199-210.
155. Abraham, S, T Sweet, K Khalili, et al: Evidence for activation of the TGF-beta1 promoter by C/EBPbeta and its modulation by Smads. J. Interferon Cytokine Res. 29 (2009), 1-7.
156. Bataille, F, C Rohrmeier, R Bates, et al: Evidence for a role of epithelial mesenchymal transition during pathogenesis of fistulae in Crohn's disease. Inflamm. Bowel Dis. 14 (2008), 1514-1527.
157. Buckley, ST, C Medina, C Ehrhardt: Differential susceptibility to epithelial-mesenchymal transition (EMT) of alveolar, bronchial and intestinal epithelial cells in vitro and the effect of angiotensin II receptor inhibition. Cell. Tissue Res. 342 (2010), 39-51.
158. Stadnicki, A, G Machnik, E Klimacka-Nawrot, et al: Transforming growth factor-beta1 and its receptors in patients with ulcerative colitis. Int. Immunopharmacol. 9 (2009), 761-766.
159. Feagins, LA. Role of transforming growth factor-β in inflammatory bowel disease and colitis-associated colon cancer. Inflamm. Bowel Dis. 16 (2010), 1963-1968.
160. Avraham, T, S Daluvoy, J Zampell, et al: Blockade of transforming growth factor-1 accelerates lymphatic regeneration during wound repair. Am. J. Pathol. 177 (2010), 3202-3214.
161. Yan, A, T Avraham, JC Zampell, et al: Adipose-derived stem cells promote lymphangiogenesis in response to VEGF-C stimulation or TGF-β1 inhibition. Future Oncol. 7 (2011), 1457-73.
162. Brightbill, HD, DH Libraty, SR Krutzik, et al: Host defense mechanisms triggered by microbial lipoproteins through toll-like receptors. Science 285 (1999), 732-736.
163. Takeuchi, O, K Hoshino, S Akira: Cutting edge: TLR2-deficient and MyD88-deficient mice are highly susceptible to Staphylococcus aureus infection. J. Immunol. 165 (2000), 5392-5396.
164. Alexopoulou, L, AC Holt, R Medzhitov, et al: Recognition of double-stranded RNA and activation of NF-kappaB by toll-like receptor 3. Nature 413 (2001), 732-738. (Pubitemid 33009951)
165. Tapping, RI, S Akashi, K Miyake, et al: Toll-like receptor 4, but not toll-like receptor 2, is a signaling receptor for Escherichia and Salmonella lipopolysaccharides. J. Immunol. 165 (2000), 5780-5787.
166. Hayashi, F, KD Smith, A Ozinsky, et al: The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5. Nature 410 (2001), 1099-1103. (Pubitemid 32391041)
167. Diebold, SS, M Montoya, H Unger, et al: Viral infection switches non-plasmacytoid dendritic cells into high interferon producers. Nature 424 (2003), 324-328. (Pubitemid 36899375)
168. Heil, F, H Hemmi, H Hochrein, et al: Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science 303 (2004), 1526-1529. (Pubitemid 38314424)
169. Pegu, A, S Qin, BA Fallert Junecko, et al: Human lymphatic endothelial cells express multiple functional TLRs. J. Immunol. 180 (2008), 3399-3405.
170. Garrafa, E, L Imberti, G Tiberio, et al: Heterogeneous expression of toll-like receptors in lymphatic endothelial cells derived from different tissues. Immunol. Cell. Biol. 89 (2011), 475-481.
171. Patel, M, J Olinde, A Tatum, et al: Gut sterilization in experimental colitis leukocyte mediated colon injury, and effects on angiogenesis/ lymphangiogenesis. Open J. Gastroenterol. 3 (2013), 12-24.
172. Wang, S-L, Z-R Wang, C-Q Yang: Meta-analysis of broad-spectrum antibiotic therapy in patients with active inflammatory bowel disease. Exp. Ther. Med. 4 (2012), 1051-1056.
173. Lee, KM, CS McKimmie, DS Gilchrist, et al: D6 facilitates cellular migration and fluid flow to lymph nodes by suppressing lymphatic congestion. Blood 118 (2011), 6220-6229.
174. Bordon, Y, CA Hansell, DP Sester, et al: The atypical chemokine receptor D6 contributes to the development of experimental colitis. J. Immunol. 182 (2009), 5032-5040.
175. McKimmie, CS, AR Fraser, C Hansell, et al: Hemopoietic cell expression of the chemokine decoy receptor D6 is dynamic and regulated by GATA1. J. Immunol.
176. Vetrano, S, EM Borroni, A Sarukhan, et al: The lymphatic system controls intestinal inflammation and inflammation-associated colon cancer through the chemokine decoy receptor D6. Gut 59 (2010), 197-206.
177. Marchetti, C, A Casasco, A Di Nucci, et al: Endothelin and nitric oxide synthase in lymphatic endothelial cells: Immunolocalization in vivo and in vitro. Anat. Rec. 248 (1997), 490-497. (Pubitemid 27342695)
178. Reeder, LB, MK Ferguson: Endothelin-1 synthesis and receptor-mediated activity in porcine lymph vessels. J. Surg. Res. 63 (1996), 215-219. (Pubitemid 26197728)
179. Mawji, IA, PA Marsden: Perturbations in paracrine control of the circulation: Role of the endothelial-derived vasomediators, endothelin-1 and nitric oxide. Microsc. Res. Tech. 60 (2003), 46-58. (Pubitemid 36055232)
180. Zhao, J, DF van Helden: ET-1-associated vasomotion and vasospasm in lymphatic vessels of the guinea-pig mesentery. Br. J. Pharmacol. 140 (2003), 1399-1413. (Pubitemid 38067847)
181. Spinella, F, V Caprara, E Garrafa, et al: Endothelin axis induces metalloproteinase activation and invasiveness in human lymphatic endothelial cells. Can. J. Physiol. Pharmacol. 88 (2010), 782-787.
182. Morbidelli, L, C Orlando, CA Maggi, et al: Proliferation and migration of endothelial cells is promoted by endothelins via activation of ETB receptors. Am. J. Physiol. 269 (1995), H686-695.
183. Salani, D, G Taraboletti, L Rosanò, et al: Endothelin-1 induces an angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo. Am. J. Pathol. 157 (2000), 1703-1711.
184. Doboszynska, T, A Andronowska: ENOS, ET-1 and ETB-R immunoreactivities in the porcine mesometrial lymphatics during the estrous cycle. Folia Histochem. Cytobiol. 40 (2002), 269-275. (Pubitemid 34830560)
185. Doboszynska, T, A Andronowska, B Modzelewska: Endothelin-1 and endothelial nitric oxide synthase immunoreactivity in lymphatic vessels of the uterine broad ligament during the estrous cycle in the pig. Cells Tissues Organs 171 (2002), 152-161. (Pubitemid 34827774)
186. Yu, W, Z Lin, JP Hegarty, et al: Genes regulated by Nkx2-3 in siRNA-mediated knockdown B cells: Implication of endothelin-1 1 inflammatory bowel disease. Mol. Genet. Metab. 100 (2010), 88-95.
187. Tabibiazar, R, L Cheung, J Han, et al: Inflammatory manifestations of experimental lymphatic insufficiency. PLoS Med. 3 (2006), e254.
188. Huggenberger, R, S Ullmann, ST Proulx, et al: Stimulation of lymphangiogenesis via VEGFR-3 inhibits chronic skin inflammation. J. Exp. Med. 207 (2010), 2255-2269.
189. Mäkinen, T, T Veikkola, S Mustjoki, et al: Isolated lymphatic endothelial cells transduce growth, survival and migratory signals via the VEGF-C/D receptor VEGFR-3. EMBO J. 20 (2001), 4762-4773. (Pubitemid 32848629)
190. Polzer, K, D Baeten, A Soleiman, et al: Tumour necrosis factor blockade increases lymphangiogenesis in murine and human arthritic joints. Ann. Rheum. Dis. 67 (2008), 1610-1616.